Shareholder Tools

Press Releases

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Nov 3, 2015 - Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies - - Conference Call Today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today annou...
Oct 27, 2015 WEST LAFAYETTE, Ind., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Nov. 3rd, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast o...
Sep 21, 2015 WEST LAFAYETTE, Ind., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will be presented at the European Cancer Congress 2015, b...
Sep 7, 2015 WEST LAFAYETTE, Ind., Sept. 7, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), today presented the final overall survival (OS) analysis from the Phase 2b TARGET trial evaluating its small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in patients with FR positive recurrent NSCLC at the World Conference on Lung Cance...
Sep 3, 2015 WEST LAFAYETTE, Ind., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the following upcoming healthcare conferences. Baird 2015 Healt...
Aug 12, 2015 WEST LAFAYETTE, Ind., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a bio-pharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that six posters will be presented by Endocyte scienti...
Aug 4, 2015 - Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies - - Final Overall Survival Analysis From TARGET Trial of EC145 in NSCLC to be Presented at the World Conference on Lung Cancer in September - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NA...
Aug 4, 2015 WEST LAFAYETTE, Ind., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Alison A. Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., M...
Aug 3, 2015 WEST LAFAYETTE, Ind., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the 2...
Jul 28, 2015 WEST LAFAYETTE, Ind., July 28, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 4th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast ...
1
... NextLast
Add to Briefcase = add release to Briefcase